{
  "url": "https://openlegislation.uk/national-health-service-pharmaceutical-and-local-pharmaceutical-services-regulations-2013/regulation-55",
  "json_url": "https://openlegislation.uk/national-health-service-pharmaceutical-and-local-pharmaceutical-services-regulations-2013/regulation-55.json",
  "legislation": "uksi/2013/349",
  "legislation_title": "The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013",
  "legislation_url": "https://openlegislation.uk/national-health-service-pharmaceutical-and-local-pharmaceutical-services-regulations-2013",
  "path": "regulation/55",
  "kind": "regulation",
  "number": "55",
  "heading": "Premises approval: relocations of practice premises which are not significant after outline consent has taken effect",
  "text": "(1) A dispensing doctor (D) who—\n(a) is providing pharmaceutical services at or from listed dispensing premises; and\n(b) wishes to relocate and dispense from new medical practice premises in relation to the area for which D has outline consent,\nmay apply in writing to NHS England for premises approval for the new medical practice premises at or from which D wishes to dispense.\n(2) Subject to paragraph (3), NHS England must grant that application if it is of the type described in this paragraph, that is to say if NHS England is satisfied that—\n(a) for the patient groups that are accustomed to accessing pharmaceutical services at or from the existing premises, the location of the new premises is not significantly less accessible;\n(b) granting the application would not result in a significant change to the arrangements that are in place for the provision of pharmaceutical services (including by a person on a dispensing doctor list) or of local pharmaceutical services—\n(i) in any part of the area of the relevant HWB, or\n(ii) in a controlled locality in the area of a neighbouring HWB, where that controlled locality is within 1.6 kilometres of the premises to which the applicant is seeking to relocate; and\n(c) NHS England is satisfied that granting the application would not cause significant detriment to proper planning in respect of the provision of pharmaceutical services in the area of the relevant HWB.\n(3) NHS England must, unless it has good cause not to do so, refuse an application under paragraph (1) if an application under—\n(a) that paragraph;\n(b) regulation 55(1) of the 2012 Regulations (premises approval: relocations of practice premises which are not significant after outline consent has taken effect); or\n(c) regulation 65(4)(a) of the 2005 Regulations (premises approval: additional and new premises after outline consent has taken effect),\nhas been granted to D during the 12 months before the application was submitted under paragraph (1).\n(4) NHS England must notify its decision in relation to the application under paragraph (1) to the persons to whom it notified the application who made representations in relation to it under regulation 52(4), and it must include with the notification of its decision an explanation of—\n(a) the reasons for the decision; and\n(b) if the person notified is a person with rights of appeal under regulation 63(1)(c) or (d), an explanation of how those rights may be exercised.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Words in reg. 55(1)(a) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 35(2)(a)"
    },
    {
      "type": "F",
      "label": "F2",
      "text": "Words in Regulations substituted (6.11.2023) by The Health and Care Act 2022 (Further Consequential Amendments) (No. 2) Regulations 2023 (S.I. 2023/1071), reg. 1(1), Sch. para. 1"
    },
    {
      "type": "F",
      "label": "F3",
      "text": "Words in reg. 55(1) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 35(2)(b)"
    },
    {
      "type": "F",
      "label": "F4",
      "text": "Words in reg. 55(2)(a) inserted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 35(3)"
    },
    {
      "type": "M",
      "label": "M1",
      "text": "Prior to its revocation, regulation 65 was amended by S.I. 2006/3373."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2013/349/regulation/55",
    "retrieved_at": "2026-10-29T01:03:55.705659+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}